Dana-Farber @DanaFarber · 26 Aug 2026
The @FDA has approved daraxonrasib for adult patients with previously treated metastatic pancreatic cancer. The approval is based primarily on results from the Dana-Farber-led RASolute 302 trial showing daraxonrasib nearly doubled median overall survival versus chemotherapy. https://t.co/RGwwbeIciw
3 712Views
61Likes
16Reposts
5Replies
1Quotes
1Bookmarks
Is that a lot?
1.31×vs this author's median2 830 views is typical
75Percentile for this authorof 4 recent posts
0.17×vs 100K–1M median21 891 views is typical
3.30%Reachviews ÷ followers
2.24%Engagement rateof viewers reacted